ArticleDrugs in context2025
Nurses' perceptions on the usability of the Hyrimoz
Article in Drugs in context, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hyrimoz Methods: Eligible participants included nurses in the USA currently working within a gastroenterology practice with experience managing inflammatory bowel disease and with reference to adalimumab, Humira Results: A total of 123 nurses completed the survey. Participants rated simplicity of use, ease of performing self-injection, ease of learning to use the pen, ability to use an autoinjector pen independently and ease of preparation as the most important autoinjector attributes. When evaluating devices individually, participants awarded higher ratings to the Hyrimoz Sensoready pen over the Humira pen for all evaluated attributes. The greatest differences were reported for visual feedback mechanisms, ease of performing self-injection and the process to initiate injection. When directly comparing the devices, participants preferred the Hyrimoz Sensoready pen over the Humira pen overall, and for all individual attributes. Visual feedback and buttonless activation were the main qualitative features driving this overall preference. Conclusion: Gastroenterology nurses in the USA expressed strong preferences for the Hyrimoz Sensoready pen
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.